Aurinia Pharmaceuticals Inc.
A biopharmaceutical company in Victoria, British Columbia, that develops and sells treatments for autoimmune diseases. Its signature drug, LUPKYNIS (voclosporin), is an oral medicine for adults with lupus nephritis, a kidney inflammation caused by lupus. The company began in 1993 in Edmonton as Isotechnika Pharma, then took the Aurinia name in 2013 when it acquired Aurinia Pharma Corp. and refocused on voclosporin; the drug won US approval in 2021. The brand name Lupkynis blends "lupus" with a distinctive suffix, and "Aurinia" also names a golden-flowered garden plant called basket of gold.
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors.
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors.
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors.
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Chin Kyu Huh | 13D/AActivist | 4.4% | 5.91M | Aug 26, 2026 |
| ILJIN SNT Co., Ltd. | 13D/AActivist | 3.7% | 4.99M | Aug 26, 2026 |
| ILJIN GLS Co., Ltd. | 13D/AActivist | 3.7% | 4.99M | Aug 26, 2026 |
| ILJIN Steel Co., Ltd. | 13D/AActivist | 0.7% | 923.6K | Aug 26, 2026 |
| Sae Kyoung Huh | 13D/AActivist | 0.4% | 465.8K | Aug 26, 2026 |
| Seoung Eun Huh | 13D/AActivist | 0.1% | 167.1K | Aug 26, 2026 |
| TANG CAPITAL MANAGEMENT, LLC | 13D/AActivist | 10% | 13.04M | Jun 4, 2026 |
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors. | ||||
| KEVIN TANG | 13D/AActivist | 10% | 13.04M | Jun 4, 2026 |
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors. | ||||
| TANG CAPITAL PARTNERS, LP | 13D/AActivist | 5.6% | 7.21M | Jun 4, 2026 |
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors. | ||||
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | 13D/AActivist | 4% | 5.24M | Jun 4, 2026 |
Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors. | ||||